BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:11 am Sale | 2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -2,736,613 (Position Closed) | Filing |
| 2023-02-14 11:58 am Sale | 2022-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 2,736,613 5.100% | -267,266 (-8.90%) | Filing |
| 2021-10-29 4:29 pm Purchase | 2021-10-21 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 3,003,879 6.500% | 3,003,879 (New Position) | Filing |